Condition (MeSH)
Osteochondritis Dissecans
ClinicalTrials.gov lists 28 trials for Osteochondritis Dissecans or a narrower condition beneath it. Zimmer Orthobiologics, Inc. has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
28 of the 28 trials are tagged with Osteochondritis Dissecans itself; the rest are tagged with a narrower condition beneath it.
When did Osteochondritis Dissecans trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 3
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 1 |
| 2022 | 1 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 2 |
| 2013 | 1 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Osteochondritis Dissecans trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 3 | 3 |
| Phase 4 | 1 |
| Not applicable | 10 |
| Observational | 12 |
How many Osteochondritis Dissecans trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 6 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 2 |
| Completed | 7 |
| Terminated | 2 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Osteochondritis Dissecans trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Zimmer Orthobiologics, Inc. | 3 |
| DePuy Mitek | 1 |
| Fin-Ceramica Faenza Spa | 1 |
| Geistlich Pharma AG | 1 |
Which drugs are being tested for Osteochondritis Dissecans? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| MACI | 1 |
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| [PRP] platelet rich plasma | 1 |
| CS-ACI | 1 |
| MRI | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Osteochondritis Dissecans? (22)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Current concepts: pathology in the overhead athlete's lateral elbow. | Journal of shoulder and elbow surgery | 2024 | Yes |
| Transarticular Versus Retroarticular Drilling of Stable Osteochondritis Dissecans of the Knee: A Prospective Multicenter Randomized Controlled Trial by the ROCK Group. | The American journal of sports medicine | 2023 | Yes |
| Matrix-assisted chondrocyte transplantation with bone grafting for knee osteochondritis dissecans: stable results at 12 years. | Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA | 2021 | Yes |
| Osteochondritis Dissecans of the Knee: Etiology and Pathogenetic Mechanisms. A Systematic Review. | Cartilage | 2020 | Yes |
| Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of an osteochondral lesion of the ankle. | BMJ case reports | 2020 | Yes |
Showing 5 of 22 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Osteochondritis dissecans | Point prevalence | 1-5 / 10 000 | Europe | Not stated | Unspecified |
| Osteochondritis dissecans | Point prevalence | 1-5 / 10 000 | Europe | Not stated | Exact |
| Osteochondritis dissecans | Point prevalence | 1-5 / 10 000 | Europe | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Osteochondritis dissecans | 2764 | Exact | Orphadata Science knowledge files, Product 1 |
| Osteochondritis dissecans | 2764 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.